[Preliminary study on the effect of the third generation flow diverter device in the treatment of intracranial aneurysms].

<b>Objective:</b> To investigate the clinical effect of the third diverter device in the treatment of intracranial aneurysms. <b>Methods:</b> This is a retrospective case series study. A retrospective study was conducted on patients with intracranial aneurysms treated with the new flow-diverting device at the Department of Neurosurgery, Peking University Third Hospital from March 2023 to February 2024. There were 11 males and 27 females, aged (58.6±12.9) years (range: 27 to 82 years). All patients underwent digital subtraction angiography(DSA) at the time of surgery to observe the stent position, wall apposition. The degree of aneurysm embolization was evaluated using the O'Kelly-Marotta (OKM) grading system,with OKM grade D as complete occlusion. The incidence of perioperative intracranial hemorrhagic and ischemic complications was recorded. The modified Rankin Scale (mRS) was used to assess patients' neurological function at discharge. CT angiography and DSA were performed 6 to 12 months postoperatively to evaluate the stent position and aneurysm embolization. <b>Results:</b> A total of 38 patients with 39 intracranial aneurysms were treated using 40 stents, with coil embolization applied to 6 aneurysms. No ischemic or hemorrhagic events occurred during the perioperative period. At discharge, all patients had an mRS score of 0. During follow-up, one patient with an ophthalmic artery segment aneurysm experienced transient monocular blindness. Imaging follow-up by DSA showed that the complete aneurysm occlusion rate was 89.7%(35/39) at 6 months and 96.8%(30/31)at 12 months. <b>Conclusion:</b> The flow-diverting device demonstrates a low complication rate and a high aneurysm occlusion rate, which is a clinically optional treatment approach.